- Experimental Combined Immunotherapy of Tumours with Major Histocompatibility Complex Class I Downregulation2018 | Faculty of Science
- Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma +12022 | Faculty of Medicine in Hradec Králové
- Combined immunotherapy improves outcome for replication repair deficient (RRD) high-grade glioma failing anti-PD1 monotherapy: A report from the International RRD Consortium2024 | Second Faculty of Medicine
- Importance of the Immune System and Immunotherapeutic Options in Malignant Melanoma2015 | Publication without faculty affiliation
- A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade2023 | First Faculty of Medicine, Second Faculty of Medicine
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Faculty of Medicine in Pilsen
- Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy2024 | Publication without faculty affiliation
- Metastatic melanoma - when and how it should by treated2016 | Publication without faculty affiliation
- Group of cancer immunotherapy and molecular epidemiology of virus infectionsPublication without faculty affiliation
- Recent advances in immunotherapy for metastatic colorectal cancer2023 | Publication without faculty affiliation
- Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer2019 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Medicine in Hradec Králové
- Advances in Immunotherapy of Malignant Melanoma2017 | Publication without faculty affiliation
- Gastrointestinal Toxicity of Immunotherapy2020 | First Faculty of Medicine
- Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules2019 | Faculty of Science
- Abrogation of IFN-gamma Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade2020 | Faculty of Science
- Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade2020 | Faculty of Science
- FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer2009 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Avelumab plus axitinib combination in treating metastatic renal cell carcinoma2022 | First Faculty of Medicine
- Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation2021 | Faculty of Science